Medication Updates
Browse by Year:
Browse by Medication:   


 
FDA Medication Updates
Medication news, updates and drug safety information on non-controlled substances.
DEA 2010 Pharmacist’s Manual
Guide to Federal Controlled Substances Act and its regulations as they pertain to the pharmacy profession.
NIMH Mental Health Medications Guide
Types of meds used to treat mental disorders, side effects, directions for taking, and FDA warnings.

2014

   
Tramadol placed into Schedule IV of Controlled Substances Act
All regulatory requirements applicable to schedule IV controlled substances apply to tramadol beginning 8/18/14.
Lunesta/Eszopiclone Containing Sleep Aids - Can Cause Next-Day Impairment
FDA issued warning that Lunesta can cause next-day impairment of activities requiring alertness. Recommended starting dose of1 mg at bedtime.
FDA approves hand-held auto-injector to reverse opioid overdose
Evzio (naloxone hydrochloride injection) rapidly delivers a single dose of naloxone via a hand-held auto-injector.
     
FDA approves Farxiga to treat type 2 diabetes
FDA approved Farxiga (dapaglifozin) tablets to improve glycemic control, with diet and exercise, in adults with type 2 diabetes.
FDA approves Tanzeum to treat type 2 diabetes
Tanzeum is a glucagon-like peptide-1 (GLP-1) receptor agonist, a hormone that helps normalize blood sugar levels.
Effexor XR 150 Mg Extended-Release Capsules & Venlafaxine HCl 150 Mg Extended-Release Capsules Recall
Recall due to possible presence of Tiosyn (dofetilide) capsules.
     

2013

   
Methylphenidate ADHD Medications: Risk of Long-lasting Erections
FDA warns that methylphenidate products may in rare instances cause prolonged and sometimes painful erections known as priapism.
Opioids Effective for Restless Legs Syndrome
Study found that prolonged-release opioid treatment produced relief of symptoms in patients with severe restless legs syndrome.
National Drug Threat Assessment
DEA provides a look at the many challenges communities face related to drug abuse and trafficking.
     
First Generic Versions of Cymbalta Approved
FDA approved the first generic versions of Cymbalta (duloxetine delayed-release capsules), used to treat depression and other conditions.
Zyprexa Relprevv (Olanzapine Pamoate)
FDA investigating 2 unexplained deaths in patients who received an intramuscular injection of the antipsychotic drug Zyprexa Relprevv.
Federal Guidelines for Managing Occupational Exposures to HIV
PEP regimens in the guidelines encourage consistent use of a combination of three or more drugs that are better tolerated
     
Zolpidem
FDA has approved label changes specifying new dosing recommendations for zolpidem products
Zolpidem
SAMHSA DAWN Report: Increase in Emergency Department visits for adverse reactions involving Zolpidem
OxyContin
FDA approves abuse-deterrent labeling for reformulated OxyContin.
     
Antipsychotics in Adults
Clinician summary on antipsychotics for schizophrenia and bipolar disorder
Benztropine Mesylate Injection
Fresenius Kabi USA is voluntarily recalling four lots of Benztropine Mesylate Injection
Rosiglitazone-containing diabetes medicine - 2010 FDA Restrictions Removed
Data does not show increased risk of heart attack.